Sagimet Biosciences Inc.
12
2
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
16.7%
2 terminated/withdrawn out of 12 trials
77.8%
-8.7% vs industry average
17%
2 trials in Phase 3/4
43%
3 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
Role: lead
A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
Role: lead
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
Role: collaborator
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Role: collaborator
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
Role: lead
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
Role: lead
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
Role: lead
Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome
Role: collaborator
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Role: lead
A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Role: lead
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects
Role: lead
A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors
Role: lead
All 12 trials loaded